Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amrubicin - Celgene Corporation/Sumitomo Dainippon Pharma

Drug Profile

Amrubicin - Celgene Corporation/Sumitomo Dainippon Pharma

Alternative Names: Amrubicin hydrochloride; Calsed; CNF3140; SM-5887

Latest Information Update: 22 Apr 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dainippon Sumitomo Pharma
  • Developer Celgene Corporation; Icahn School of Medicine at Mount Sinai; SCRI Development Innovations; Stanford University; Sumitomo Dainippon Pharma
  • Class Anthracyclines; Antineoplastics; Cytostatic antibiotics; Small molecules
  • Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer; Small cell lung cancer
  • Phase II Thymoma
  • Phase I/II Breast cancer; Multiple myeloma
  • Discontinued Bladder cancer

Most Recent Events

  • 31 Dec 2018 Celgene and Stanford University completes a phase II trial in Thymoma (Second-line therapy or greater, Metastatic disease) in USA (IV) (NCT01364727)
  • 24 Jun 2018 Biomarkers information updated
  • 22 Jun 2015 Amrubicin is still in Preregistration for Small cell lung cancer (First-line therapy) in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top